ARAY vs. UTMD, CTSO, SPNE, ANIK, SRDX, OFIX, ANGO, RMTI, RSLS, and ABT
Should you be buying Accuray stock or one of its competitors? The main competitors of Accuray include Utah Medical Products (UTMD), Cytosorbents (CTSO), SeaSpine (SPNE), Anika Therapeutics (ANIK), Surmodics (SRDX), Orthofix Medical (OFIX), AngioDynamics (ANGO), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "medical" sector.
Utah Medical Products (NASDAQ:UTMD) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
Utah Medical Products has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Accuray has a consensus target price of $8.25, suggesting a potential upside of 364.79%. Given Utah Medical Products' higher possible upside, analysts plainly believe Accuray is more favorable than Utah Medical Products.
In the previous week, Utah Medical Products and Utah Medical Products both had 1 articles in the media. Accuray's average media sentiment score of 1.84 beat Utah Medical Products' score of 0.31 indicating that Utah Medical Products is being referred to more favorably in the media.
Utah Medical Products has a net margin of 33.40% compared to Utah Medical Products' net margin of -4.99%. Accuray's return on equity of 13.06% beat Utah Medical Products' return on equity.
69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 6.6% of Utah Medical Products shares are held by insiders. Comparatively, 3.8% of Accuray shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Accuray received 179 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 65.67% of users gave Accuray an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
Utah Medical Products has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Summary
Utah Medical Products beats Accuray on 10 of the 16 factors compared between the two stocks.
Get Accuray News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
